Nabriva Therapeutics AG (NASDAQ:NBRV) Receives $15.89 Consensus PT from Brokerages
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) have received a consensus rating of “Buy” from the seven research firms that are covering the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.89.
NBRV has been the topic of a number of research reports. Zacks Investment Research cut Nabriva Therapeutics AG from a “buy” rating to a “hold” rating and set a $8.25 price objective on the stock. in a report on Friday, September 23rd. HC Wainwright started coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th.
Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 7.1005 on Wednesday. The firm’s market capitalization is $150.94 million. Nabriva Therapeutics AG has a 12 month low of $6.61 and a 12 month high of $10.69. The stock’s 50 day moving average price is $7.50 and its 200-day moving average price is $7.92.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.50) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($6.25) by $5.75. Equities analysts anticipate that Nabriva Therapeutics AG will post ($1.93) EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Vivo Capital LLC acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth $28,239,000. Opaleye Management Inc. raised its stake in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares in the last quarter. Finally, Jackson Park Capital LLC acquired a new stake in shares of Nabriva Therapeutics AG during the second quarter worth $195,000. Hedge funds and other institutional investors own 63.05% of the company’s stock.
About Nabriva Therapeutics AG
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.